Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, discusses findings from the TROPION-Breast01 study on ...

Roflumilast demonstrated effectiveness and safety in treating psoriasis, with added benefits for patients with comorbidities.

Pemphigus is a rare autoimmune disease that causes painful blisters on the skin and mucous membranes, including the mouth, ...

Individuals on immunosuppressants should discontinue them prior to patch testing, if at all possible, to avoid tarnishing the test results, according to updated guidelines from the North American ...

Cold weather, dry air, an overactive immune system or our modern lifestyle. The causes may vary, but an increasing number of ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...

The global atopic dermatitis treatment market is on the cusp of remarkable expansion, with projections indicating a surge in ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...